ArticleMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V2026
An introduction to polygenic scores - methodological basics and recent advances.
Article in Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polygenic scores (PGS) allow the estimation of genetic predisposition to complex diseases and traits. Based on results from genome-wide association studies (GWAS) and data from large deeply phenotyped population biobanks, numerous PGS have been developed in recent years. These scores summarize the combined effects of many genetic variants and can support risk stratification for multifactorial diseases based on an individual's genetic susceptibility. In this review, we introduce the basic principles and methods of PGS and explain how they are generated and applied. We outline their potential translational role, particularly in the context of precision medicine and personalized risk stratification for preventive measures, in combination with established clinical risk factors. At the same time, we discuss important limitations, including limited generalizability across populations and the issue of missing heritability. Finally, we highlight current methodological developments and future perspectives for the integration of PGS into clinical practice.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.